Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions reflect strong support and interest in the article, with examples like references to '89% efficacy,' comments on the importance of early treatment within 3 days, and debates on study design and sample size. The tone is analytical and supportive, emphasizing the significance of the findings in improving COVID-19 management.
Most comments support the positive findings of the publication, highlighting efficacy and safety, indicating general consensus.
There is high curiosity about the study results and implications, with many referencing specific data and studies.
Discussions delve into detailed analysis, comparisons with other studies, and questions about methodology.
The social discussions acknowledge the potential influence of the research on treatment practices and public health policies.
パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the control arm. https://t.co/NqB9nGRyhB
The blog starts with Hammond (2022), the original NEJM trial that started it all. https://t.co/kOXdQVp2UY Zero deaths vs. 7 for placebo. NNT of 17 for combination of hosp/death. Not bad! 7/ https://t.co/Jw71Gm8K9A
重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi: 10.1056/NEJMoa2118542. Online ahead of print. PMID:35172054 https://t.co/QkU9yx2Vmn
パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/aus9I3BGmK https://t.co/agyGwnA3oy https://t.co/PteaAamicR
The Omicron variant of SARS-CoV-2 exhibits less efficient replication and cell fusion activity compared to the Delta variant, particularly in TMPRSS2-expressing cells. It primarily uses the endocytic pathway for…
This week, John Mandrola MD examines statin intolerance and the impact of new medications like finerenone on chronic kidney disease in type 2 diabetes. He discusses the effectiveness of finerenone in reducing…
@Fynnderella1 @RMConservative @CoffeeandaMike https://t.co/4DOqrD6sE4
@grok @Ja_vajos @JanTakje_II @RichelTheo @Theo_Roy33 They are not replicated if they are flawed. Allowing dosing to start beyond day 3 as a design (not sub group) means it is flawed. Per the following Paxlovid study "dosing within 3 days of symptoms" Replicate Design or it is flawed. https://t.co/3SDoT1uOFL
@real_seeking @tunackr2020 @redpilldispensr Paxlovids approval started with a double blinded study if over 2000 patients https://t.co/lQftW39i08 https://t.co/Ve6n3eiuS5
@OliveJenkins911 @thehealthb0t Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower. Source- New England Journal of Medicine https://t.co/6LCeL7R8Eu
重溫經典： Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | New England Journal of Medicine https://t.co/vqlQEhXiUB
@dr_francisco79 Aqui: https://t.co/QcHVYFJtO5 O senhor deveria perceber a diferença nas populações/recomendações. Poderia estudar um pouco mais em vez de perder tempo discutindo com IA em rede social ou processando quem faz piada.
@tropic_health @naomirwolf That is this study: https://t.co/JmyVhVUfes What are you on about?
@C_A_G0101 @MeMeDocMa @nicolasberrod @pimp_renelle @nathanpsmad oui, et non. EPIC-HR est ici: https://t.co/nlfMbzRB9S comme dit ci dessus, le nirmatrelvir REDUIT LA MORTALITE! OUI! Mais, chez des patients non vaccinés recrutés en 2021. L'autre étude ci dessus, randomisée inclue des patients de fin 2021 juqu'en juillet 22 à 50% vaccinés
Please remind us how antivirals should be used: within 5 days after symptom onset. https://t.co/Cy41eb2ZqJ https://t.co/O4YxHPBoZR and that it failed when the treatment is delayed https://t.co/1hWdPB8H5c https://t.co/pJQLsMK1Uo 2/2
@LedenUnor @craigbyren @ElipieMegan @HeatherEHeying @AndrewEcker829 Paxlovid Dosing every 12 hours for 5 days Treated within 3 days after symptom onset ALSO: Started 5 days of symptoms but had to extract 3 days max to pass https://t.co/3SDoT1uOFL
@Indig0star @WhiteL_o_t_u_s @sudokuvariante @LoLoWarn @Lavisjuste1 @Apoo52105617 P.S. Pour en rajouter une couche sur à quel point l'argument du "80 events c'était pas assez pour publier Dans l'essai du Paxlovid, qui a carrément donné lieu à une AMM (vous conviendrez que les AMM sont plus difficiles à avoir que les publications) https://t.co/rIOoSfDe4q 4/n https://t.co/IwyAvfqsKu
@dr_jon_l @yeahnaa333 @donkerwater Paxlovid Dosing every 12 hours for 5 days Treated within 3 days after symptom onset ALSO: Started 5 days of symptoms but had to extract 3 days max to pass https://t.co/3SDoT1ugQd
@dr_jon_l @jamesamcgee @ZombiApocolypse Paxlovid Dosing every 12 hours for 5 days Treated within 3 days after symptom onset ALSO: Started 5 days of symptoms but had to extract 3 days max to pass https://t.co/3SDoT1ugQd
RT @helenaddy: @nicolafiore Google is full of links to studies about the clinical trials of Paxlovid. It's been taken by hundreds of thousa…
@nicolafiore Google is full of links to studies about the clinical trials of Paxlovid. It's been taken by hundreds of thousands of people. If you don't want to take it, fine whatever, but some of us need to in order to survive a SARS infection. https://t.co/6bKUhWGz2V
Oups c'est ballot https://t.co/wX6YSrJKEE
RT @LoLoWarn: @jmdogne alors qu'il est efficace chez les personnes à risque en précoce. https://t.co/ySKZJWFuZD
RT @LoLoWarn: @jmdogne alors qu'il est efficace chez les personnes à risque en précoce. https://t.co/ySKZJWFuZD
@jmdogne alors qu'il est efficace chez les personnes à risque en précoce. https://t.co/ySKZJWFuZD
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
Paxlovid does not shorten duration of illness but greatly reduces severe illness in high risk patents. It is under prescribed for older adults and other high risk groups. pubmed.ncbi.nlm.nih.gov/35172054/
@Jason https://t.co/ShKGNP7lCK
@Debunk_the_Funk @TheChiefNerd For those literally impaired, https://t.co/LpuSZRMlyQ
@fluidloading @tim_riggins330 @voks45 @JeanKev_Apeupre @lonnibesancon @RChabriet Et non, tu connais les règles de l’EBM, l’avis d’expert ça vaut rien face à un rct chez des personnes à risque. Encore une fois tu fais de l’EBM à géométrie variable. https://t.co/ySKZJWFuZD https://t.co/6gRnqJY9Ut
https://t.co/3DxTEcIRD9
@07DanTheman7 @BarryHunt008 No drug can be marketed without trials. Do some fact checking: https://t.co/6eD7Ydnl5T
Voici deux bons exemples pour le remdesivir et le paxlovid dont les deux études portent sur du soins précoce et personnes à risques (Merci Karine) https://t.co/ySKZJWFuZD https://t.co/gNiJX4QCD1 https://t.co/eHwqbeZeWR
RT @black_kghp: https://t.co/R8VJcrldKN
RT @ld97RfGZu8FfzWH: @hikaruganji ワクチン主成分がグラフェンだとすると、排出は瀉血以外にほぼ不可であって伝播不可では? Pfizerプロトコルに記載される'Exposure'経路は、1.母体→胎児、２.母乳、3.医療従事者からとあり。1と2は血…
@hikaruganji ワクチン主成分がグラフェンだとすると、排出は瀉血以外にほぼ不可であって伝播不可では? Pfizerプロトコルに記載される'Exposure'経路は、1.母体→胎児、２.母乳、3.医療従事者からとあり。1と2は血液感染。3は急性放射線症候群ではないでしょうか? https://t.co/lBqVpMfBx0
@Jeannemarie1309 @RedPandaPills @pjd77420 @gentilhomme65 @M_Alazon https://t.co/DKYnqDKrjR (pas de conflits d'interets) https://t.co/9RJVN0aCz4 (pas de conflits d'interets) https://t.co/rKDix66qvz (pas de conflits d'interets) https://t.co/tKIFzWDu7l
@lebon80 @CitizenXSci @EricBillyFR @sudokuvariante 2246 personnes pour le paxlovid. https://t.co/eHuUFmkswO En UNE SEULE étude, pas en 50. Donc biiien plus significatif que tes 1500 personnes.
@BradBanko @DrPaulOffit "viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment" . https://t.co/0bw4VcgfDj
@BradBanko @DrPaulOffit That is not true, it is based on gold standard DBRCT but it is VERY carefully curated one! actually so curated that all subsequent stuies were not allowed! https://t.co/uvBcTAFkgn "Pfizer has denied access to Paxlovid for independent RCTs Ledford" https://t.co/iNFENWLnsg
@MartyMakary This paper looks at Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. https://t.co/TQ05v0sSMJ https://t.co/3R1Cgq0YOC
RT @real_seeking: @I_am_Steele @AlyssaDAMinIt @Anne_Gee_2923 @DrEtiquette @ZaleskiLuke Paxlovid Dosing every 12 hours for 5 days Treated wi…
@I_am_Steele @AlyssaDAMinIt @Anne_Gee_2923 @DrEtiquette @ZaleskiLuke Paxlovid Dosing every 12 hours for 5 days Treated within 3 days after symptom onset ALSO: Started 5 days of symptoms but had to extract 3 days max to pass https://t.co/3SDoT1ugQd
@anish_koka @shycollie Not going to come at you with anecdotal success stories but what is your criticism of this? https://t.co/Ffn1Q2dH0b
@Debunk_the_Funk @TheChiefNerd Paxlovid was only over indicated to work in unvaccinated adults at high risk of severe COVID-19 who had not been infected https://t.co/cCxgSAreUy By the time the FDA authorized paxlovid for use in the US in late 2021 https://t.co/KWeEXcThYo Combined seroprevalence from https://t.co/i93BS4MPDV
@ryanbeed @Cornholio2024 @cbeckj @MB05076 @LaceyForostoski @villagerssn @ThomMohr @PeaceLillie33 @RaggetteU @Iwontsubmit @HealthFreedomLA Didn’t take much time for this one.
@mauri_perez El ensayo original de paxlovid fue positivo, por muy poco y con endpoint blando, pero positivo. El tema era ver qué psaba en vacunados y post exposición. https://t.co/DGDHgdB5Kj
@catturd2 Also, a 2022 study showed 20 hospitalizations & 7 deaths in the placebo group with 3 hospitalizations & 0 deaths in the group that received So this obviously decreases hospitalizations & death, but keep cherry pick the results for your ignorant MAGA base https://t.co/TvbQAi20wl
@ChanceGardiner Continui a scrivere cazzate https://t.co/rhxwzGxkcb Vedi se riesci a capirci qualcosa
@Debunk_the_Funk @TheChiefNerd This is the study stating the 89% relative risk. Different patient population that the one Nerd is presenting. Not overly impressed with this one as the incidence was small in both groups and the absolute risk reduction is small. https://t.co/0GIETKc97e
@MaxDelvallee @NEJM Et précision de taille @MaxDelvallee , il se pourrait sur cette étude l’administration du paxlovid soit un poil trop tardif comparé à l’étude pivot du pax (non hosp) alors qu’ici ils sont hospitalisé et pour une grande partie au moins sous oxygène https://t.co/ySKZJWFuZD
@KinseyKat1 @ryanbeed @PeaceLillie33 @LaceyForostoski @Iwontsubmit @HealthFreedomLA Since he seems reluctant to show the study I will link it here so people can look at the whole picture. Look at the actual percentages and not just the RR. I am also suspicious of the 13 deaths in placebo group with none in the trial arm. https://t.co/0GIETKc97e
@CraigKellyPHON 1/ Craig, I know you don't read peer reviewed papers, but here's a double-blind, randomized, controlled trial of Paxlovid published in February 2022, when the participants would have had the Delta variant (Omicron appeared Dec. 2021) It was effective. https://t.co/wn9vN8zHK8 https://t.co/tXTu5fMzqj
@fluidloading bah voici donc l'etude de #Pfizer en personne (pas facile à trouver je dois dire) 89% d'efficacité qui disent!! du coup pfizer ment... ou c'est toi? https://t.co/Masf2E4loO https://t.co/zXFykgpiqE
@dukla_DE @OliverFaude @ewyler Einige links (die nicht notwendigerweise meine Interpretation stützen). EPIC-HR: https://t.co/RA3CEjJbUv NEJM Editorial zu EPIC-SR: https://t.co/WzFtQNXpAQ Ärzte Blatt 2022 zu EPIC-SR: https://t.co/WzFtQNXpAQ
@AstorAaron @Rando8715401 The results of EPIC-HR have been known for a long time. That study was published two years ago. https://t.co/GkY7LTzZT1
@zeynep @simoj_ Of course EPIC-HR was a trial, but it only included unvaccinated people and didn’t include a sufficient number of immunocompromised patients to make any meaningful conclusions. And I’ve never claimed that observational evidence is zero evidence. https://t.co/otD8fksCex https://t.co/9pFlr1tEHR
Pour référence le bénéfice existait en 2022 pour les patients à hauts risques. Avec l’évolution de l’immunité en population et des variants moins létaux à voir si cela perdure https://t.co/wsq79oZfiH
@think_fungus On a les info pour high risk. https://t.co/wsq79oZfiH
@docdu16 Cela peut dépendre du niveau de risque. Ça ne présente peut-être plus de bénéfice aujourd’hui car l’immunité de la population a évolué, phénomène de moisson, virus moins létal car variant/clade différent, etc . https://t.co/wsq79oZfiH
RT @MathieuMolimard: Bénéfique chez les patients à risque (DOI: 10.1056/NEJMoa2118542), le nirmatrelvir/ritonavir perd son intérêt dans les…
Bénéfique chez les patients à risque (DOI: 10.1056/NEJMoa2118542), le nirmatrelvir/ritonavir perd son intérêt dans les populations à faible risque (DOI: 10.1056/NEJMoa2309003). Le bénéfice -risque d'un médicament dépend plus du patient et de l'indication que du médicament https://t.co/kkgNTnwO3U https://t.co/1uH7bOhMO0
Die RCT zu Paxlovid (links) ist ein schönes Statement. Nicht für Paxlovid, sondern für die Impfung, wenn man sie im Kontext der EPIC-HR-Studie liest (rechts). https://t.co/Sg1Loh65i3 https://t.co/o0XmiWme2G https://t.co/mWizHde04x
@Universal_Ken @Amy_Walker20 @Melchizedek1972 @LymeScience @MdBreathe @myedpillus Paxlovid Dosing every 12 hours for 5 days Treated within 3 days after symptom onset ALSO: Started 5 days of symptoms but had to extract 3 days max to pass https://t.co/3SDoT1ugQd
@ryanbeed @AtomsksSanakan @ptcjoneses @TakethatCt @Vaxed2DaMax @JonathanSarfat1 @mobindondon @KStateTurk @TigerlillySusan @villagerssn @notagr0wer @TrevorHifi @tamlarge @DiegoHAWK6 @Lunatic__Fringe @DrAcula987 @DrSusanOliver1 It's right here... Look at results: "treated within 3 days after symptom onset" https://t.co/3SDoT1ugQd
@ryanbeed @AtomsksSanakan @ptcjoneses @TakethatCt @Vaxed2DaMax @JonathanSarfat1 @mobindondon @KStateTurk @TigerlillySusan @villagerssn @notagr0wer @TrevorHifi @tamlarge @DiegoHAWK6 @Lunatic__Fringe @DrAcula987 @DrSusanOliver1 https://t.co/3SDoT1ugQd
@BHater2022 @DanishTechGuy @yay_its_james Link to specific tweet that do "thorough debunking" Yes sample size is small, and patient selection is biased in wrong direction (low risk/mild), what do you think would be p-value if it was 3x larger size and patients at risk selection like here? https://t.co/uvBcTAFkgn
RT @jvipondmd: The blog starts with Hammond (2022), the original NEJM trial that started it all. https://t.co/kOXdQVp2UY Zero deaths vs. 7…
RT @jvipondmd: The blog starts with Hammond (2022), the original NEJM trial that started it all. https://t.co/kOXdQVp2UY Zero deaths vs. 7…
The blog starts with Hammond (2022), the original NEJM trial that started it all. https://t.co/kOXdQVp2UY Zero deaths vs. 7 for placebo. NNT of 17 for combination of hosp/death. Not bad! 7/ https://t.co/Jw71Gm8K9A
@DocDeezWhat @SummnaS @BGatesIsaPyscho Paxlovid Dosing every 12 hours for 5 days Treated within 3 days after symptom onset https://t.co/3SDoT1ugQd
@DrSuneelDhand No, the COVID drug Paxlovid is not dangerous and ineffective. Several studies show Paxlovid reduces COVID mortality and is safe https://t.co/GGqYlJX6pq https://t.co/ZpccmhCa6w
@GavinBr25762121 @RmLiberty @GidMK The guy is
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
RT @jvipondmd: Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the…
Study 1: 89% RRR (6% ARR or NNT of 17) in bad outcomes (hospitalization/death). zero deaths in the active arm, vs. 13 in the control arm. https://t.co/NqB9nGRyhB
RT @jvipondmd: A reminder that the paxlovid arm had zero (ZERO!) deaths compared to 13 in the placebo arm. for high risk patients. https:/…
A reminder that the paxlovid arm had zero (ZERO!) deaths compared to 13 in the placebo arm. for high risk patients. https://t.co/NqB9nGRyhB
@DCDoc33 Paxlovid is milquetoast (weak). Read the NEJM article below. The NHS of the UK just dumped it after wasting 2B. Low dose lithium is powerful, and safer (read the second paper, mine) but Big Pharma would prefer it remain unknown. https://t.co/lDZXLFiOSY https://t.co/g6TIrPEvgQ
@masimaux @sudokuvariante @boulware_dr The fact that this IVM study was done on very healthy-low risk (and is used as doesn't work argument) and PAX one on at high-risk patients tells you about study design bias from author! https://t.co/uvBcTAFkgn it is amazing that you see benefit despite bias regardless!
@a_huss1 @ingomar_gutmann "Eligible patients were required to be at least 18 years old; to have confirmed SARS-CoV-2 infection and symptom onset no more than 5 days before randomization, with at least one sign or symptom of Covid-19 on the day of randomization" https://t.co/dCpTNogMps https://t.co/0H7pxekJJP
@Johann_Dupuis Paxlovid: Pfizer: https://t.co/O4YxHPARaj Essai positif, publié rapidement Pfizer: https://t.co/eneHcB1tXI https://t.co/dQ8LsZMjEw résultats négatifs: non publiés 3/n
@domstadtmedicus naja, es gibt eine Zulassungsstudie. https://t.co/rvJtSEB9QA wir haben ja auch keine dauerhaften Studien zu Antibiotikagabe bei Infekten. Paxlovid ist zugelassen und sollte Indikationsgerecht eingesetzt werden. Ich gebe es häufig/biete es häufig an. Nicht jeder will es.
RT @sudokuvariante: Sources. Viral load: https://t.co/Zt9XqvB2ws https://t.co/O4YxHPARaj https://t.co/wgCb3POS72 PeP trials: https://t.co/Q…
Sources. Viral load: https://t.co/Zt9XqvB2ws https://t.co/O4YxHPARaj https://t.co/wgCb3POS72 PeP trials: https://t.co/QcNCznrtH2 https://t.co/dQ8LsZMjEw https://t.co/vShjnh1CBb
RT @sudokuvariante: I made a new graph comparing viral load reduction in Ivermectin Chaccour trial https://t.co/Zt9XqvB2ws and paxlovid Ham…
EPIC-HR-tutkimuksen perusteella ihmishengen hinta ei siis ole 500 euroa, vaan paljon enemmän. 3/3 https://t.co/ER6SHp0Y2G
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/DCU4sZqj0m
@Jeannemarie1309
@DATSUN260ZG @NMyqwnHlC8vioIJ @skyblue_nurse 更に言えば 同じ厚労省(PMDA)試験で承認された薬剤もあります。 この薬剤は3日目以降でも効果がありました(検討事項は新型コロナでの入院、何らかの原因での死亡で異なる、また患者背景や感染株も異なる)。 https://t.co/KiPzmuIUeD https://t.co/XL2vSfBFNs
@TBkowski @medexit ...bo albo też nie czytali, albo nie zrozumieli, albo wybrali sobie z tego to, co im pasowało pod tezę. tu jest podział, którego nie widzą - na hosp. i zgony. ba. jest nawet na wiek (<65 i >65), oraz czas rozp. leczenia (<3d i >3d) [2/n] https://t.co/3k7xImm22t
En un ensayo doble ciego, aleatorizado, controlado, con adultos sintomáticos, no vacunados y no hospitalizados, y alto riesgo de COVID-19 grave, el uso de nirmatrelvir más ritonavir redujo incidencia de hospitalización o muerte por esta enfermedad https://t.co/N3d6BLLQ1t
RT @MIDCUSA: Lots of discussion regarding Paxlovid rebound. Nirmatrelvir is a Mpro protease inhibitor. Does mutation of Mpro explain the re…
@Ltdantheman76 @simoncynicsays @Anymous84861064 @kevinnbass @US_FDA BS argument, it will not reach stat sig. BY DESIGN! Compare it with this one: https://t.co/uvBcTAFS5V Very carefully crafted (look at numbers 4x more, exclusions trough the roof, number of centers used is insane), now do the stat.for those # maintaining OR p goes to 0.000x
@Jeannemarie1309 @Sq178kin @Beerussamarange @bitchwitch1969 @bonnesante73 @nicorlando1980 @SahabiaAli @Titithebest4 https://t.co/C8szn3Baqe De rien. Mais t’as pas le niveau
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
Tuvimos la dicha de participar en el grupo de investigadores de este antiviral especifico contra COVID-19, sumando armas al arsenal anti pandemia https://t.co/TNkEw4ib4B https://t.co/As9GpaJJkF
@Christian_NDBy ...aber doch in nem zweiten Arm auch bis zu 5 Tage nach Symptombeginn überprüft und einen Effekt gezeigt. Das ist ja schon ne Hausnummer bei SARS-CoV-2 und würde ich als "späte Einnahme" gelten lassen. https://t.co/C47vQ5z8Yj https://t.co/4wakDrkHax
@JSanders174 @RI2APAC @LEPfedup @GovDanMcKee .@GovDanMcKee is at high risk for COVID-19 complications by virtue of his age; keep in mind that approximately 60% of the US population has at least one high-risk factor. https://t.co/Wzy2WsRD0e
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM
@dokhollidays @Kirsche16473791 @a_usem @GieslerIris @Karl_Lauterbach @US_FDA Problematik bzgl Rebound ist bereits Thema einiger Studien, siehe zB: ▶️ https://t.co/Xc005nzVKz ▶️ Hier finden sich des Weiteren div Studien: https://t.co/nYhHylSxDj Ach so, Ursprungsstudie für die Notfall-EUA 12/21: https://t.co/p5fVy16fiT = 1120 Patienten bekamen Paxlovid, 3/
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 was examined in an article by Hammond et al. in NEJM. Read more here: https://t.co/ysUTBDXTzB
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/iLp5gZeviL
@renkon33211147 @MidoriyaShimiz ワクチンや他の治療薬は、たとえば下記のような臨床試験できちんと”臨床上重要な指標”での改善が確認された上で承認されています。 ファイザー https://t.co/IYOklKP0oC モデルナ https://t.co/A9o4jGAqo7 パキロビッド https://t.co/QkU9yx2Vmn ラゲブリオ https://t.co/upvctNbuBN
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/k6XVzNjkWT
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/rKuRGwW5wh
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. New Engl J Med 2022; 386(15): 1397-1408. https://t.co/0NL1LE5N7O
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/ZRwcRnA8Py
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
RT @naika_hashikure: 一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
一方でファイザーのパクスロビドの試験では発症3日以内の投与が過半数で、中央値が3日です。 https://t.co/QleCaBhgoC https://t.co/hduykmv1FH
@BC_Irma_Stretch The trial is here published in the NEJM. https://t.co/byQgBoWESA Yah 6% of people report a crappy metallic taste. Lot of meds don't taste great. I have been recommended people wear proper masks for more than two years... Best
RT @CarlosdelRio7: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/9UMpBEgtNL Finally the Paxlovid stud…
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/U1fT40xaYm
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/89tVuTWeXz
@Northofwestward @EricTopol That's the SR study (standard risk) the original study is the HR study (high risk) This is the original trial: https://t.co/TrtlDk9w9S
Risk for progression to severe COVID-19 lower with nirmatrelvir + ritonavir https://t.co/cQC38PAuJJ https://t.co/zrJumTDd7x https://t.co/Mk6PmiQQ5T https://t.co/Ua9QMYa5pX
RT @MIDCUSA: Lots of discussion regarding Paxlovid rebound. Nirmatrelvir is a Mpro protease inhibitor. Does mutation of Mpro explain the re…
Lots of discussion regarding Paxlovid rebound. Nirmatrelvir is a Mpro protease inhibitor. Does mutation of Mpro explain the relapse? https://t.co/5HWAZkAmU4 had 731 matched samples with no association between Mpro mutation and Rx failure. #paxlovidrebound https://t.co/lAgkHB6wNg
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/ppZCEraQUQ
In der Zulassungsstudie (https://t.co/kT75SkvMJH) führte dies zu einer Reduktion schwerer bzw. tödlicher Covid-19-Verläufe um ca. 88 %. Falls diese Therapie wegen Kontraindikationen oder Wechselwirkungen nicht angewendet werden kann, gibt es dazu noch mehrere Alternativen. 10/12
RT @juisci:
@epkuAwait_99 @slipknothooh @lh9983 其实包含老人了 https://t.co/MvM7N64iSb https://t.co/hx4hJUv5kL
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/02PnCs2byp
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM - https://t.co/ZwFFbcnnZ4 https://t.co/3R9Synh2fW
RT @TAEscmid: #ECCMID2022 Year in Infectious Diseases session now at Hall E #COVID Oral Nirmatrelvir for High-Risk, Nonhospitalized Adult…
RT @TAEscmid: #ECCMID2022 Year in Infectious Diseases session now at Hall E #COVID Oral Nirmatrelvir for High-Risk, Nonhospitalized Adult…
RT @TAEscmid: #ECCMID2022 Year in Infectious Diseases session now at Hall E #COVID Oral Nirmatrelvir for High-Risk, Nonhospitalized Adult…
4) HAMMOND, Jennifer et al.. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England Journal of Medicine, v.386, n.15, p.1397-1408, 2022. Disponível em: <https://t.co/cEHyyc33rM>.
Paxlovid es el tratamiento de elección vs SARS Cov2, aún no está disponible en México. ¿Habremos de llegar a las 800 mil defunciones para que se disponga de él? Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/iSZz3PW33b
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/XRUSD49yUY
RT @JohnHRandall1: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/QXGzAhUFkC
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/QXGzAhUFkC
パクスロビド(日本名パキロビッドパック)の第2/3相臨床試験(治験)結果 日本語版Abstract 高リスクの入院していない成人 Covid-19 患者に対する経口ニルマトレルビル Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 J. Hammond and Others https://t.co/yHnKnflHNQ
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/8Jpprr2uOQ
RT @adamcifu: These are impressive results. I'd expect the ARR would be a lot less in a vaccinated/previously exposed population but still.…
RT @adamcifu: These are impressive results. I'd expect the ARR would be a lot less in a vaccinated/previously exposed population but still.…
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/o5IH8eQmAa
RT @JohnHRandall1: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/LFUdcNBYUo
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/LFUdcNBYUo
RT @adamcifu: These are impressive results. I'd expect the ARR would be a lot less in a vaccinated/previously exposed population but still.…
These are impressive results. I'd expect the ARR would be a lot less in a vaccinated/previously exposed population but still... Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/A8k54vK4JE
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/6ciuqrX5uB The US Pharmaceutical and Biotech industries and their scientific staffs have produced both vaccines and treatments in a record time to suppress the COVID epidemic.
RT @VivekSubbiah: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 @NEJM https://t.co/9dr2l4HWo6
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/vNCvsIai8a
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM @nejm @AnnalsofIM https://t.co/DC0wGQjCVh
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 @NEJM https://t.co/9dr2l4HWo6
@heidi_monkkonen @lasleh @hsfi Tehoa, jos aloitus 1-3vrk sisällä. Ei enää 4-5pv kuluttua! In the planned interim analysis of patients treated within 3 days after symptom onset the incidence of Covid-19-related hospitalization or death by day 28 was lower https://t.co/iIV7oN7ECI
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/llY2dkHkCZ
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. https://t.co/rTu1svfdjv
2/ @DrJacksonCork discussed the NEJM oral nirmatrelvir study: https://t.co/SgGWdd2Sfl Hopefully some of you were able to join the @IDJClub last night as well for a deeper dive! Can scroll thru #IDJClub for more!
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
RT @ykfrs1217: パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
パキロビットの３相試験。死亡や入院を90%以上減らすのは素晴らしい！けど、5%近くの人に味覚障害がでる（プラセボの10倍以上）のは患者さんにめっちゃ文句ゆわれそう…。怖 https://t.co/TInQG1ULzP
PCR必須？ みなしで使えるなら対象は広がるかな チェック大変だけど https://t.co/isdR9ayVIv
ファイザーの経口薬（日本での販売名パキロビッド）の治験論文 Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/89qTVWKSU1
@NoDictatorship9 @nuhope2022 @tomsirolimus @mhunt081266 @F250Roush @PLHartungRN @sammy44231 @zeetubes @AndrewLazarus4 @Monstercoyliar @ogilville1 @SkepticalMutant @MatthewNewell67 @BrexitMyArse @mcfunny @AbsoluteGnosis @raouldukeerik @JimeeLiberty @TonyBaduy @volpiranyas @provaxtexan @IdunsDaughter @KayVonPaul @Alex_on_A14 @NoMisinfoToday @DbootyNabber @doom37455413 @richykirsh @kath2cats @jtmayes3 @doritmi @ninawowp @MarkTho29550016 @xfirgaming @ConsequentialBr @lewbloch @tatsandfats @JonathanHannah @SallyJiggles @andylumm @3dogrunner @MagnoliaHoney2 @CHSdoctor @chimera414 @Nockit1 @skepticalprune @LandonNTooke @SeamusMacSuibh1 @Fannyi5 @jallen1315 doi = digital object identifier It's the link to a paper Such as the one I used for the very recent paper on the protease inhibitor clinical trial https://t.co/92pUebewQi
@F250Roush @PLHartungRN @NoDictatorship9 @jtmayes3 @sammy44231 @tomsirolimus @mhunt081266 @zeetubes @AndrewLazarus4 @Monstercoyliar @ogilville1 @SkepticalMutant @MatthewNewell67 @BrexitMyArse @mcfunny @nuhope2022 @AbsoluteGnosis @raouldukeerik @JimeeLiberty @TonyBaduy @volpiranyas @provaxtexan @IdunsDaughter @KayVonPaul @Alex_on_A14 @NoMisinfoToday @DbootyNabber @doom37455413 @richykirsh @kath2cats @doritmi @ninawowp @MarkTho29550016 @xfirgaming @ConsequentialBr @lewbloch @tatsandfats @JonathanHannah @SallyJiggles @andylumm @3dogrunner @MagnoliaHoney2 @CHSdoctor @chimera414 @Nockit1 @skepticalprune @LandonNTooke @SeamusMacSuibh1 @Fannyi5 @jallen1315 Yes, specific protease inhibitor as COVID makes a very large proto-protein which must be cleaved into functional pieces for the virus to replicate Yes, needs to be given early in infection Data look good https://t.co/Xl7EEQDEWU And NEJM early
RT @JohnHRandall1: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/UO88OK92wM
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/UO88OK92wM
@CVimmunology @Hartmann_KE I guess this is what I get for being behind on NEJM: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/p7wDVP8dkq
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @Pediatria: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/J9UfA3GtlH
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/J9UfA3GtlH
RT @alidoc7: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/ZbMlPLlABG
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/ZbMlPLlABG
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/tWEQgQpbPK
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/OaUfLTGjmG
Some good news for early treatment of vulnerable individuals with COVID infections Hammond et al "Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19" NEJM early online 2022 https://t.co/92pUebewQi
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/QPStoccDOX
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/3Ol1vokDoj
impressive results: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/Li5VLB81Sr
RT @drjohnmorley: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/zrthF05uNm
#論文紹介 ファイザーの経口投与訳、ニルマトレルビルのRCT論文が出ました！ 効果は重症化のリスクを約90%低下させており、重篤な有害事象も無かったということ。死亡に関しては、プラセボ7人、ニルマトレルビル0人でした。 https://t.co/wZHt7djnMA https://t.co/kfM9lzl4O6
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/WJJOih5xHD
Confirmation of good #COVID19 news
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/P8fngxq2Jd
#medtwitter How excited should we get? Will this 1. help 2. anytime soon? Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/cUEJF9UJpR
RT @CarlosdelRio7: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/9UMpBEgtNL Finally the Paxlovid stud…
Trend up+4: Hammond J, ..., Epic-hr Investigators (N Engl J Med) __Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19__ https://t.co/BB9ZS61IvI
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/wNmIeSs4F4
COVID-19 経口治療薬パクスロビド 、高リスク COVID-19 症例の入院および死亡リスクを89%軽減 (2022-006) 凄まじい薬効
Oral #Nirmatrelvir for High-Risk, Nonhospitalized Adults with #Covid-19 | NEJM https://t.co/mxwaqxrszT
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/psUjv8A72C
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/dxuwY8BzHP
RT @SFManchaC: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @gunnar_heine: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/kuFHoslSii here comes the next…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @NAChristakis: Amazing: placebo-controlled randomized trial of oral Paxlovid (N=2246) shows 89% efficacy vs COVID hospitalization or dea…
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
#未読 https://t.co/SZ8742sWFy https://t.co/OjskrFV9yO https://t.co/k48FsGqECj https://t.co/zKBIx3ApnG https://t.co/BY5fpfJ2zJ https://t.co/NxooxdAEKK
The second is: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. https://t.co/qS7qORg21O
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
RT @carpe_diem0820: パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Or…
パキロビッドの臨床研究報告 Covid-19発症者にニルマトレルビルとリトナビルの併用で、重症化リスクを89%低減 安全性の明らかな懸念はなしも下記は増加 味覚障害(5.6% vs. 0.3%) 下痢 (3.1% vs. 1.6%) Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/aus9I3BGmK https://t.co/agyGwnA3oy https://t.co/PteaAamicR
RT @Aller_MD: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM https://t.co/BEgRe7K8PY
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://t.co/zKBIx3jmlG
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
RT @Fizz_DI: 重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi…
重症化リスクのあるCOVID-19患者に対する「パキロビッド：ニルマトレルビル300mg＋リトナビル100mg」の5日間投与は、プラセボに比べ、28日間の入院または死亡を88.9％抑制。 N Engl J Med . 2022 Feb 16. doi: 10.1056/NEJMoa2118542. Online ahead of print. PMID:35172054 https://t.co/QkU9yx2Vmn
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна — мета-анализы не ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна — мета-анализы не ...
doi: 10.1056/NEJMoa2118542. Epub ahead of print. PMID: 35172054; PMCID: PMC8908851. #SARS-CoV-2 #COVID19 ...
同薬は、EPIC-HRで、高リスクで合併症のある有症状（曝露後）COVID-19成人非入院患者への効果・安全性が示されている（https://www.nejm.org/doi/full/10.1056/NEJMoa2118542） ...
doi: 10.1056/NEJMoa2118542. pmid:35172054. 6. Syed AM, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, et al. Omicron mutations enhance infectivity and ...
org/doi/full/10.1056/NEJMoa2118542 SC DHEC Evusheld Antibody Treatment for COVID-19 High-risk Groups Vanderbilt University Medical Center Antibodies ...
https://www.nejm. org/doi/full/10.1056/NEJMoa2118542?fbclid=IwAR39 rTFTNKUGHUjRo90ZhzBBqzf5cP6xbaBj_BvO2qBDfzy Fmm-q4E12wrQ.
... 10.1056/NEJMoa2118542?articleTools=true. Editor's Note: Dr. Ebell is deputy editor for evidence-based medicine for AFP and cofounder and editor-in-chief of ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
org/doi/full/10.1056/NEJMoa2118542 https://www.bmj.com/content/375/bmj.n2713 https://clinicaltrials.gov/ct2/show/NCT04960202 #covid19 #covid ...
Источник: https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 НЕпоказательные работы Арбидол - мало регистрированных серий и мета-анализов ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы Арбидол - мало ... 10.1056/NEJMoa2007764 Нирматрелвир + ритонавирё — RCT у высокого риска ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
Источник: https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 НЕпоказательные работы Арбидол - мало регистрированных серий и мета-анализов ...
org/doi/full/10.1056/NEJMoa2118542 https://www.bmj.com/content/375/bmj.n2713 https://clinicaltrials.gov/ct2/show/NCT04960202 #covid19 #covid ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 · https://pmc.ncbi.nlm.nih.gov/articles/PMC9214014/. If you're a high risk adult and get ...
... Pfizer…but so was sr i think. https://www.nejm.org/doi/full/10.1056/NEJMoa2118542. Panoramic still hasn't published. There are more. [deleted].
org/doi/full/10.1056/NEJMoa2118542 https://www.bmj.com/content/375/bmj.n2713 https://clinicaltrials.gov/ct2/show/NCT04960202 #covid19 #covid ...
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
... https://www.nejm. org/doi/full/10.1056/NEJMoa2118542. nejm.org. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with. 3 yrs · Mo Kaye.
... 10.1056/NEJMoa2118542 НЕпоказательные работы. Арбидол - мало регистрированных серий и мета-анализов; суммарно доказательность неоднородна ...
2022;doi:10.1056/NEJMoa2118542. Hammond J, et al. N Engl J Med. 2024;doi:10.1056/NEJMoa2309003. Mafi JN, et al. JAMA. 2025;doi:10.1001/jama ...
doi:10.1056/NEJMoa2118542. 2. Hammond J, Fountaine RJ, Yunis C, et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with ...
... time not actually protection from more severe disease. https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 · dace154288. • 1y ago.
... 10.1056/NEJMoa2118542). An der Studie nahmen 2246 nicht gegen Covid-19 geimpfte Patienten mit symptomatischem Covid-19 teil, die zwar nicht ...
org/doi/10.1056/NEJMoa2118542. nejm.org. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with. 2 yrs. Michael Kelleher Jr. Jason Parker ...
doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. PMID: 35172054. Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, Lv Y, Guan X, Yang Y, Ye X, Deng X ...
https://www.nejm.org/doi/full/10.1056/nejmoa2118542. If you can find a peer reviewed, evidence based study showing Paxlovid's benefit in ...
doi: 10.1056/NEJMoa2118542. Hettle D, Hutchings S, Muir P & Moran E. COVID-19 Genomics UK (COG-UK) consortium. Persistent SARS-CoV-2 ...
Published online February 16, 2022:NEJMoa2118542. doi:10.1056/NEJMoa2118542 #香港感染及傳染病醫學會 #香港 #傳染病 #感染控制 #冬季感染 ...
2022;doi:10.1056/NEJMoa2118542. Kuehn BM. JAMA. 2022;doi:10.1001/jama.2022.20036. Najjar-Debbiny R, et al. Clin Infect Dis. 2022 ...
doi:10.1056/nejmoa2118542. 7. Gilead Sciences. Study Evaluating GS-5245 in Participants With COVID-19 Who Have a High Risk of Developing ...
https://www.nejm.org/doi/full/10.1056/nejmoa2118542. As for interactions, atorvastatin should be held during Paxlovid use, but the patient's ...
doi: 10.1056/NEJMoa2118542. Bernal AJ et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2022; 386 ...
doi:10.1056/NEJMoa2118542. 4. Callaway E. COVID rebound is surprisingly common - even without Paxlovid. Nature. Published online August 11 ...
Sompob Saensuk. Mi Muthita ปกติ คนทั่วไปเค้าไม่อ่านกันนะ Paxlovid https://www.nejm. org/doi/10.1056/NEJMoa2118542. nejm.org. Oral Nirmatrelvir ...
... 10.1056/nejmoa2118542. [3] Luana Colloca and Franklin G. Miller. “The Nocebo Effect and Its Relevance for Clinical Practice.” Psychosomatic ...
... 10.1056/NEJMoa2118542 https://www.bmj.com/content/375/bmj.n2713 https://clinicaltrials.gov/ct2/show/NCT04960202 #covid19 #covid ...
... 那是因为本来就很少了（而且样本量小也没帮上忙）。 还是，8倍啊，哥们。 编辑： https://www.nejm.org/doi/full/10.1056/NEJMoa2118542. [已删除]. • 3年前.
doi:10.1056/nejmoa2118542. 15. Gupta K, Strymish J, Stack G, et al. Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early ...
... 10.1056/NEJMoa2118542]: Bu çalışmanın verilerine göre, riskli hastalarda Covid olup hastaneye kaldırılma veya Covid'den ölme tehlikesi ...
New England Journal of Medicine. Vol. 386, April 14, 2022, p. 1397. doi: 10.1056/NEJMoa2118542. K. Gupta et al. Rapid relapse of symptomatic ...
org/doi/full/10.1056/NEJMoa2118542. nejm.org. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-. 4 yrs. 肝炎資訊及病友權益.
2022 Feb 16:NEJMoa2118542. doi: 10.1056/NEJMoa2118542. Epub ahead of print. PMID: 35172054 NCT04960202. The Methods. This is a phase 2/3 ...
DOI: 10.1056/NEJMoa2118542. Eric J. Rubin et al, The Potential of Intentional Drug Development, New England Journal of Medicine (2022). DOI ...
... 10.1056/NEJMoa2118542). An der Studie nahmen 2246 nicht gegen Covid-19 geimpfte Patienten mit symptomatischem Covid-19 teil, die zwar nicht ...
... 10.1056/NEJMoa2118542). An der Studie nahmen 2246 nicht gegen Covid-19 geimpfte Patienten mit symptomatischem Covid-19 teil, die zwar nicht ...
... 10.1056/NEJMoa2118191 EPIC-HR DOI: 10.1056/NEJMoa2118542 #clinicamedica #medicinainterna #covid_19 #nirmatrelvir #avc #trombectomia".
doi:10.1056/NEJMoa211854 https://www.nejm.org/doi/full/10.1056/NEJMoa2118542. Currently rated 2.0 by 1 person. Posted in: Medical Research ...
Pfizer published their trial results today: https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 Almost all hospilizations happened until day ...
... Covid-19" N Engl J Med 2022; DOI: 10.1056/NEJMoa2118542. 1. 1 Comment. Please enable JavaScript to view the comments powered by Disqus.
org/doi/full/10.1056/NEJMoa2118542?fbclid=IwAR39 rTFTNKUGHUjRo90ZhzBBqzf5cP6xbaBj_BvO2qBDfzy Fmm-q4E12wrQ. Oral Nirmatrelvir for High-Risk ...
org/doi/pdf/10.1056/NEJMoa2118542?articleTools=tr ue My thesis: politicians/lawyers should not prescribe health policy unsupervised. Even if ...
org/doi/full/10.1056/NEJMoa2118542 https://www.bmj.com/content/375/bmj.n2713 https://clinicaltrials.gov/ct2/show/NCT04960202 #covid19 #covid ...
Y古
内
J
FY
M無
GD
S
ED
TH
DB
M
DA
FS
L
NE
DB
E
PF
LL
DF
D
PR
う
入
NK
H
UI
NF
CM
AD
JG
DE
KK
DM
NF
A
P
JR
CJ
KK
JM
EB
D
PM
DR
BH
SJ
HS
D
M
AW
NO
V
CC
AF
NI
S
D
FV
DW
PM
S
JK
MM
MB
お
KH
ǤX
MA
F
P
LO
K
MB
PR
AR
TT
YE
MM
?
MP
ニ
うФ
ᵧᾥ
ビ
亜
T
も
N
G
ブ
AY
藤C
せ
ニ
星
A
C
L
SS
へ面
ダ完
JM
KF
DL
B
K
AB
VF
MC
AF
HH
M
JC
SP
C
JM
AB
BS
JA
دA
F
FM
DR
JB
AC
RG
NP
IP
AM
VM
T
AG
IS
F
F
ｺ
M
さ
や
Y
い
A
S敗
春回
さ
ぴ
たド
H
フ
チ
葉
ク
広
ブ
EΛ
S
JJ
LC
下
中S
JO
CH
MN
CB
KF
AS
DB
HA
H
AE
SD
TM
P食
TW
G
ÑÑ
M
P
AG
TL
NS
猫
A
AM
密C
JG
TW
CM
MF
FC
B
CF
P
B
DD
W
青
C
T智
M
感
I
あ
TK
メ薬
みM
T